Initial experience from a pilot project that provides drug developers with a one-stop shop for seeking scientific advice simultaneously from two EU members states has shown that the concept is working well and can be particularly useful during an emergency such as the COVID-19 pandemic.
A total of 16 simultaneous national scientific advice (SNSA) meetings have taken place for innovative products under development since the...